The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes
Abstract
Previous studies have shown that the selective aldosterone blocker eplerenone, in doses of up to 200 mg/d, reduces albuminuria in patients with type 2 diabetes. This study was conducted to ascertain whether lower doses of eplerenone (50 or 100 mg/d) co-administered with the angiotensin-converting enzyme (ACE) inhibitor enalapril would produce a similar antialbuminuric effect while obviating the hyperkalemia observed previously. After open-label run-in with enalapril 20 mg/d, patients with diabetes and a urinary albumin:creatinine ratio (UACR) > or = 50 mg/g were randomly assigned to receive enalapril plus one of three double-blind daily treatments for 12 wk: placebo, eplerenone 50 mg (EPL50), or eplerenone 100 mg (EPL100). After week 4, amlodipine 2.5 to 10 mg/d was allowed for BP control (systolic/diastolic BP < or = 130/80 mmHg). The primary study end points were the percentage change from baseline at week 12 in UACR and the incidence of hyperkalemia. Secondary end points included percentage changes from baseline in UACR at weeks 4 and 8 and changes from baseline in systolic and diastolic BP. Treatment with EPL50 or EPL100 but not placebo significantly reduced albuminuria from baseline. By week 12, UACR was reduced by 7.4% in the placebo group, by 41.0% in the EPL50 group, and by 48.4% in the EPL100 group (both eplerenone groups, P < 0.001 versus placebo). The incidences of sustained and severe hyperkalemia were not significantly different in any of the three treatment arms and did not differ on the basis of quartile of estimated GFR (all NS). For the secondary end points, both eplerenone treatment groups significantly reduced albuminuria from baseline as early as week 4 (P < 0.001), whereas placebo treatment (including enalapril) did not result in any significant decreases in UACR. Systolic BP decreased significantly in all treatment groups at all time points, but, generally, all treatment groups experienced similar decreases in BP. Co-administration of EPL50 or EPL100 with an ACE inhibitor as compared with an ACE inhibitor alone significantly reduces albuminuria in patients with diabetes without producing significant increases in hyperkalemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Rachmani, R., Slavachevsky, I., Amit, M., Levi, Z., Kedar, Y., Berla, M., & Ravid, M. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01194.x · Cited by 142
RetractedThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
(2000) · Journal of the American Society of Nephrology · Cited by 1,718
Pitt, B., Wj, R., Zannad, F. M., Neaton, J. D., Martínez, F. A., Roniker, B., Bittman, R. M., Hurley, S., Kleiman, J. H., & Gatlin, M. R. (2003) · Cited by 708
Angiotensin II receptor antagonists
Burnier, M., & Brunner, H. (2000) · The Lancet · doi:10.1016/s0140-6736(99)10365-9 · Cited by 707
Pitt, B., Reichek, N., Willenbrock, R., Zannad, F., Phillips, R. A., Roniker, B., Kleiman, J., Krause, S., Burns, D., & Williams, G. H. (2003) · Circulation · doi:10.1161/01.cir.0000091405.00772.6e · Cited by 623
Self-citationAldosterone/salt induces renal inflammation and fibrosis in hypertensive rats
Blasi, E. R., Rocha, R., Rudolph, A. E., Blomme, E. A. G., Polly, M. L., & McMahon, E. G. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00929.x · Cited by 542
The role of the renin-angiotensin system in the development of cardiovascular disease
Unger, T. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02321-9 · Cited by 515
Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive Rats
Rocha, R., Chander, P. N., Khanna, K., Zuckerman, A., & Stier, C. T. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.451 · Cited by 496
Aldosterone: A Mediator of Myocardial Necrosis and Renal Arteriopathy
Rocha, R. (2000) · Endocrinology · doi:10.1210/en.141.10.3871 · Cited by 475
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
Weinberger, M. H., Roniker, B., Krause, S. L., & Weiss, R. J. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)02957-6 · Cited by 388
Self-citationPitt, B., White, H., Nicolau, J., Martinez, F., Gheorghiade, M., Aschermann, M., van Veldhuisen, D. J., Zannad, F., Krum, H., Mukherjee, R., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.04.038 · Cited by 388
Self-citationThree new epoxy-spirolactone derivatives: characterization in vivo and in vitro.
de Gasparo, M., Joss, U., Ramjoué, H. P., Whitebread, S. E., Haenni, H., Schenkel, L., Kraehenbuehl, C., Biollaz, M., Grob, J., & Schmidlin, J. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22580-0 · Cited by 343
Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F., & Parving, H.-H. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2106 · Cited by 299
Aldosterone in the development and progression of renal injury
Hollenberg, N. K. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00701.x · Cited by 273
Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
Brown, N. J., Nakamura, S., Ma, L., Nakamura, I., Donnert, E., Freeman, M., Vaughan, D. E., & Fogo, A. B. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00277.x · Cited by 255
Schjoedt, K. J., Andersen, S., Rossing, P., Tarnow, L., & Parving, H.-H. (2004) · Diabetologia · doi:10.1007/s00125-004-1542-0 · Cited by 249
Beneficial impact of spironolactone in diabetic nephropathy
Schjoedt, K. J., Rossing, K., Juhl, T. R., Boomsma, F., Rossing, P., Tarnow, L., & Parving, H.-H. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00756.x · Cited by 239
Pathophysiological effects of aldosterone in cardiovascular tissues
Rocha, R., & Stier, C. T. (2001) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00432-5 · Cited by 212
Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients
Krum, H., Nolly, H., Workman, D., He, W., Roniker, B., Krause, S., & Fakouhi, K. (2002) · Hypertension · doi:10.1161/01.hyp.0000025146.19104.fe · Cited by 210
Self-citationCalcium Antagonists in Clinical Medicine
Epstein, M. (2002) · Cited by 201
Self-citationLocal Angiotensin II and Transforming Growth Factor-β1 in Renal Fibrosis of Rats
Sun, Y., Zhang, J., Zhang, J. Q., & Ramires, F. J. A. (2000) · Hypertension · doi:10.1161/01.hyp.35.5.1078 · Cited by 166
Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications
Epstein, M. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80115-3 · Cited by 158
Self-citation50th Anniversary of Aldosterone
Williams, J. S., & Williams, G. H. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030490 · Cited by 150
Self-citationAldosterone enhances angiotensin II receptor binding and inositol phosphate responses.
Ullian, M. E., Schelling, J. R., & Linas, S. L. (1992) · Hypertension · doi:10.1161/01.hyp.20.1.67 · Cited by 141
Antagonists of Aldosterone and Proteinuria in Patients With CKD: An Uncontrolled Pilot Study
Bianchi, S., Bigazzi, R., & Campese, V. M. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.03.007 · Cited by 140
Sato, A., Hayashi, K., & Saruta, T. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.06.029 · Cited by 132
Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function
Epstein, M., & Campese, V. M. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.08.040 · Cited by 117
Self-citationEpstein, M. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)02333-6 · Cited by 116
Self-citationEffects of eplerenone versus losartan in patients with low-renin hypertension
Weinberger, M. H., White, W. B., Ruilope, L. M., MacDonald, T. M., Davidson, R. C., Roniker, B., Patrick, J. L., & Krause, S. L. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.12.005 · Cited by 115
Self-citationWhite, W. B., Carr, A. A., Krause, S. L., Jordan, R., Roniker, B., & Oigman, W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00461-2 · Cited by 109
Self-citationOestreicher, E. M., Martinez-Vasquez, D., Stone, J. R., Jonasson, L., Roubsanthisuk, W., Mukasa, K., & Adler, G. K. (2003) · Circulation · doi:10.1161/01.cir.0000097000.51723.6f · Cited by 93
Epstein, M. (2001) · Journal of Hypertension · doi:10.1097/00004872-200105000-00001 · Cited by 87
Self-citationSato, A., Funder, J. W., & Saruta, T. (1999) · American Journal of Hypertension · doi:10.1016/s0895-7061(99)00066-7 · Cited by 82
Angiotensin II and trials of cardiovascular outcomes11Reprints are not available.
Sleight, P. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02322-0 · Cited by 77
Zhou, X., Ono, H., Ono, Y., & Frohlich, E. D. (2004) · American Journal of Nephrology · doi:10.1159/000077396 · Cited by 66
Ravis, W. R., Reid, S. R., Sica, D. A., & Tolbert, D. S. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005275894 · Cited by 49
Keilani, T., Danesh, F. R., Schlueter, W. A., Molteni, A., & BATLLE, D. C. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70181-2 · Cited by 28
Poulsen, P. L., Ebbehøj, E., & Mogensen, C. E. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00821.x · Cited by 27
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy
Parving, H.-H., Persson, F., Lewis, J. B., Lewis, E. J., & Hollenberg, N. K. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708379 · Cited by 1,098
Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887
Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708
Metadata
- Authors
- Epstein, M., Williams, G. H., Weinberger, M., Lewin, A., Krause, S., Mukherjee, R., Patni, R., & Beckerman, B.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2006-09
- Volume
- 1
- Issue
- 5
- Pages
- 940-951
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2132715232
- Cited by
- 459
- References
- 45
- FWCI
- 17.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.